Walleye Capital
ANAB icon

Walleye Capital’s AnaptysBio ANAB Stock Holding History

Walleye Capital’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-33,200
Closed -$540K – 896
2019
Q4 		$540K Buy
+33,200
New +$785K 0.04% 640

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Walleye Capital's ANAB Position: Q1 2026 in Review

Walleye Capital opened a new position in AnaptysBio (ANAB) in Q1 2026: 18,425 shares worth $1.02M. The stake represents ﹤0.01% of the portfolio and ranks #2056 among its holdings. This is a return to the name: Walleye Capital previously reported a position in ANAB as recently as Q3 2025.

Walleye Capital first reported a position in ANAB in Q2 2019 and has held it in 11 quarters since. The position peaked at $5.49M in Q3 2024. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • Walleye Capital held 18,425 shares of AnaptysBio worth $1.02M as of Q1 2026.
  • AnaptysBio was a new Walleye Capital position in Q1 2026.
  • AnaptysBio made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2056 holding.
  • Walleye Capital first reported a position in AnaptysBio in Q2 2019 and has held it in 11 quarters since.
  • Walleye Capital's AnaptysBio position peaked at $5.49M in Q3 2024.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.